Skip to main content

Press Releases

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Inc. Appoints Vice President of Research

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 02/08/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms, is pleased to announce that Srinivasa Madhyastha, PhD, has been appointed as the Company's vice president of research. Dr. Madhyastha joined Kane Biotech as senior scientist and manager in January 2002, and later assumed the responsibility of director of research.

"We are very fortunate to have someone with Dr. Madhyastha's expertise and credentials on our team. Our pipeline of technologies has seen rapid growth under his guidance for the past five years", stated Mr. Gord Froehlich, President of Kane Biotech Inc. "Dr. Madhyastha is ideally qualified to lead Kane Biotech's research and development program into the future and we are pleased to announce his appointment to vice president of research."

Dr. Madhyastha has over 20 years experience in scientific research, management and teaching, with over fifty publications in refereed scientific journals and three patents. Prior to joining Kane Biotech, Dr. Madhyastha held several senior research positions in the biotechnology industry including director of research and development at Viventia Biotech Inc. (formerly Novopharm Biotech Inc.) and director of research and human resources Nutratech Inc. He holds a B.Sc. in Biology and Chemistry and M.Sc. in Biochemistry and Microbiology from Mysore University, India and a PhD in Applied Microbiology from the National Institute of Nutrition, India. Dr. Madhyastha completed his Post-Doctoral Fellowship at the University of Manitoba and Auburn University, Alabama. He has also previously served as adjunct professor in the department of animal science, University of Manitoba.

"I am looking forward to leading the advancement of Kane Biotech's research and development", commented Dr. Madhyastha. "As the Company moves towards the commercialization of KBI-4258 and KBI-5898, my focus will be to expedite the development of Kane's pipeline of additional biofilm-related technologies and products for medical and industrial applications."

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Gord Froehlich

President, Kane Biotech Inc.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Kane Biotech Inc.
Sandra Benson
Manager, Investor Relations
(204) 478-5602
(204) 453-1314 (FAX)